Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of GSK 692342 TB Vaccine in Healthy Adults
NCT00621322Phase 2Completed
- Sponsor
- GSK
- Start
- Apr 2008
- Primary completion
- Apr 2009
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of M72 + AS01E in Tuberculosis (TB) (6 arms), sponsored by GSK. Primary endpoints: Number of Subjects With Solicited Local Symptoms, Number of Subjects With Solicited General Symptoms and 3 more. Started Apr 2008; status: completed.
02
Drugs
M72 + AS01E
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT00621322.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00621322.